Abstract 950P
Background
In this study, we aimed to evaluate the safety and efficacy of combining PD-1 antibody Tislelizumab with Sorafenib for the treatment of advanced hepatocellular carcinoma(HCC). Additionally, we sought to investigate the relationship between the circulating tumor cells (CTCs) count/ programmed death-ligand 1 (PD-L1) expression of CTCs and the prognosis of patients with advanced hepatocellular carcinoma.
Methods
The study Enrolled patients (pts) with unresectable HCC patients (pts) to receive tislelizumab combined with sorafenib. Tislelizumab, 200mg/q3w intravenous infusion, sorafenib 400 mg/bid oral dose; Evaluate every 3 cycles (9 weeks) to evaluate the safety and effectiveness of the drug regimen CTCs count and PD-L1 expression of CTCs were performed in all patients before enrollment. Primary endpoint was ORR by RECISTv1.1 per investigators. The secondary endpoints aimed to assess the relationship between the count of CTCs or the expression of PD-L1 and the prognosis of HCC.
Results
As of November 2022, 32 patients were enrolled in the study received combination treatment. For 32 pts, ORR was 17% (95% CI 33.0%-75.2%) and DCR was 65% (95% CI 71.2%-91.9%) by RECIST v1.1. When evaluated by mRECIST, ORR and DCR improved to 24.2% (95% CI 55.8%-93.8%) and 75% (95% CI 74.2%-92.9%), respectively. Treatment-emergent adverse events (TEAEs) occurred in 75% of pts, 35% of which was ≥grade 3. Of which 31 patients (96.8%) were positive for CTC, ranging from 1 to 45, with a median of 7 (3, 11), 25 (78.1%) PD-L1+CTC was detected in 32 patients. The median follow-up time was 6 months (range, 2-14 months). Correlation analysis found that The 1-year progression-free survival rates of patients in the PD-L1+CTC group and those in the non-detected PD-L1+CTC group were 54.1% vs 28.6% respectively (P=0.036).
Conclusions
Tislelizumab combination with Sorafenib showed promising antitumor activity with relatively high ORR and a tolerable safety profile in 1st line HCC treatment. Baseline CTC PD-L1+ can be used as a predictive indicator for screening HCC patients for PD-1/PD-L1 blockade therapy, and dynamic measurement of CTC changes can monitor the therapeutic effect of patients.
Clinical trial identification
ChiCTR2100050076.
Editorial acknowledgement
Legal entity responsible for the study
Che Xu.
Funding
Sanming Project of Medicine in Shenzhen (No.SZSM202011010) and Shenzhen High-level Hospital Construction Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18